Profil
Bill Arthur worked as the Head of Research and Vice President at Neoleukin Therapeutics, Inc. from 2021 to 2023.
Prior to this, he earned a doctorate degree from The University of North Carolina at Chapel Hill and an undergraduate degree from Western Washington University.
Anciens postes connus de Bill Arthur
| Sociétés | Poste | Fin |
|---|---|---|
| NEUROGENE INC. | Chief Tech/Sci/R&D Officer | 01/03/2023 |
Formation de Bill Arthur
| The University of North Carolina at Chapel Hill | Doctorate Degree |
| Western Washington University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |
